All In Biotech

Drug Trial Radar · NCT03017872

Dolutegravir and Darunavir Evaluation in Adults Failing Therapy

A Phase IIIB/IV Randomised Open-label Trial Comparing Dolutegravir With Pharmaco-enhanced Darunavir Versus Dolutegravir With Predetermined Nucleosides Versus Recommended Standard of Care ART Regimens in Patients With HIV-1 Infection Failing First Line Therapy.

Last checked: Nov 19, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 831 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

831

Actual

Start

Nov 23, 2017

Primary completion

Nov 11, 2022

Study completion Oct 31, 2023

Sponsor

Lead sponsor
Kirby InstituteGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
UNITAID; National Institute of Allergy and Infectious Diseases (NIAID); National Health and Medical Research Council, Australia; ViiV Healthcare; Janssen Pharmaceutica
First posted
Jan 11, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

D²EFT is a randomised, open-label study in HIV-1 infected patients failing first-line antiretroviral therapy (ART). The study compares 2 regimens of second-line ART (dolutegravir and darunavir pharmaco-enhanced with ritonavir and dolutegravir and 2 prespecified NRTIs) with the WHO recommended regimen of 2NRTIs plus a ritonavir-boosted PI (Standard of Care (SOC)). 1,010 participants from 14 predominantly low-middle income countries will be followed for 96 weeks with the primary endpoint at week 48. The design is based on the hypothesis that one or both of the new regimens will be non-inferior to SOC in terms of virologic control while being easier to take, economically viable and affording simplification of treatment programs.

Conditions

  • HIV Infections

Interventions

  • NRTIsDrug

    In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection. In D2N arm, NRTIs are predetermined.

  • DolutegravirDrug

    50mg tablet by mouth once daily for 96 weeks.

  • DarunavirDrug

    800mg tablet by mouth once daily for 96 weeks.

  • RitonavirDrug

    100mg tablet by mouth once daily for 96 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of participants in each arm whose plasma viral load is <50 copies/mL at 48 weeks by intention to treat.Time frame: At 48 weeks

Locations

28 sites in 14 countries. Site status is shown where the registry gives one.

  • Hospital Interzonal de Agudos San Juan de Dios

    La Plata, Argentina

  • Hospital Dr Diego Paroissien

    Isidro Casanova, Buenos Aires, Argentina

  • Hospital G de Agudos JM Ramos Mejia

    Buenos Aires, Buenos Aires F.D., Argentina

  • CAICI

    Rosario, Santa Fe Province, Argentina

  • Laboratório de Pesquisa Clinica Em Hiv/Aids - Instituto Nacional de Infectologia - Fiocruz

    Rio de Janeiro, Brazil

  • Hospital San Borja-Arriaran

    Santiago, Chile

  • ASISTENCIA Cientifica De Alta Complejidad S.A.S.

    Bogotá, Colombia

  • Centre de traitementambulatoire de Donka ( Hopital de jour)

    Conakry, Guinea

  • CART CRS, VHS Hospital

    Chennai, Tamil Nadu, India

  • Dr. Cipto Mangunkusumo Hospital

    Jakarta, Indonesia

  • RSUP Dr. Wahidin Sudirohusodo

    Makassar, Indonesia

  • Dr. Soetomo Hospital

    Surabaya, Indonesia

  • Dr Sardjito Hospital

    Yogyakarta, Indonesia

  • University of Malaya Medical Centre

    Kuala Lumpur, Malaysia

  • Hospital Pulau Pinang

    George Town, Pulau Pinang, Malaysia

  • University of Sciences, Techniques and Technologies of Mali, University Clinical Research Center (UCRC)

    Bamako, Mali

  • Instituto Nacional de Ciencias Medicas y Nutriciòn Salvador Zubiran

    Mexico City, Mexico

  • Morales Vargas Centro de Investigacion SC

    León, Guanajuato, Mexico

  • Hospital Civil de Guadalajara

    Guadalajara, Jalisco, Mexico

  • Institute of Human Virology, Nigeria (IHVN)

    Abuja, Nigeria

  • Desmond Tutu HIV Foundation

    Cape Town, South Africa

  • Clinical HIV Research Unit (CHRU), Wits Health Consotium (Pty) Ltd

    Johannesburg, South Africa

  • Perinatal HIV Research Unit (PHRU), Chris Hani Baragwanath Hospital

    Soweto, South Africa

  • HIV-NAT (The HIV Netherlands Australia Thailand Research Collaboration), Thai Red Cross AIDS Research Centre

    Bangkok, Thailand

  • Chiangrai Prachanukroh Hospital

    Chiang Rai, Thailand

  • Srinagarind Hospital, Khon Kaen University

    Khon Kaen, Thailand

  • Bamrasnaradura Infectious Diseases Institute

    Nonthaburi, Thailand

  • University of Zimbabwe Clinical Research Centre

    Harare, Zimbabwe

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.